Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Fig. 4

Change from baseline in MHD across patient subgroups. BL, baseline; CGRP, calcitonin gene-related peptide; CM, chronic migraine; EM, episodic migraine; GAD, generalized anxiety disorder; mAb, monoclonal antibody; MDD, major depressive disorder; MHD, monthly headache days; MO, medication overuse. aNumber of patients with available assessment at each time point

Back to article page